HRP20200410T1 - Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora - Google Patents

Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora Download PDF

Info

Publication number
HRP20200410T1
HRP20200410T1 HRP20200410TT HRP20200410T HRP20200410T1 HR P20200410 T1 HRP20200410 T1 HR P20200410T1 HR P20200410T T HRP20200410T T HR P20200410TT HR P20200410 T HRP20200410 T HR P20200410T HR P20200410 T1 HRP20200410 T1 HR P20200410T1
Authority
HR
Croatia
Prior art keywords
pyrrolo
pyridin
ethanone
methyl
fluoro
Prior art date
Application number
HRP20200410TT
Other languages
English (en)
Croatian (hr)
Inventor
Christa C. Chrovian
Michael A. Letavic
Jason C. Rech
Akinola Soyode-Johnson
Jessica L. WALL
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20200410T1 publication Critical patent/HRP20200410T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
HRP20200410TT 2015-07-09 2016-07-07 Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora HRP20200410T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators
EP16741469.7A EP3319963B1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
HRP20200410T1 true HRP20200410T1 (hr) 2020-08-21

Family

ID=56497884

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200410TT HRP20200410T1 (hr) 2015-07-09 2016-07-07 Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora

Country Status (25)

Country Link
US (2) US9963447B2 (cg-RX-API-DMAC7.html)
EP (1) EP3319963B1 (cg-RX-API-DMAC7.html)
JP (2) JP6964576B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180026760A (cg-RX-API-DMAC7.html)
CN (1) CN108026094B (cg-RX-API-DMAC7.html)
AU (1) AU2016291158B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000468A2 (cg-RX-API-DMAC7.html)
CA (1) CA2991765C (cg-RX-API-DMAC7.html)
CY (1) CY1123007T1 (cg-RX-API-DMAC7.html)
DK (1) DK3319963T3 (cg-RX-API-DMAC7.html)
EA (1) EA033197B1 (cg-RX-API-DMAC7.html)
ES (1) ES2781867T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200410T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047460T2 (cg-RX-API-DMAC7.html)
IL (1) IL256758A (cg-RX-API-DMAC7.html)
LT (1) LT3319963T (cg-RX-API-DMAC7.html)
MA (1) MA42397B1 (cg-RX-API-DMAC7.html)
MD (1) MD3319963T2 (cg-RX-API-DMAC7.html)
MX (1) MX2018000352A (cg-RX-API-DMAC7.html)
PL (1) PL3319963T3 (cg-RX-API-DMAC7.html)
PT (1) PT3319963T (cg-RX-API-DMAC7.html)
SI (1) SI3319963T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000134T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017007938A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800827B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
HRP20200410T1 (hr) * 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) * 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
JP7346441B2 (ja) * 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用
TW202112774A (zh) * 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并-吡啶醯胺及其作為glun2b受體調節劑之用途
JP2022536424A (ja) * 2019-06-14 2022-08-16 ヤンセン ファーマシューティカ エヌ.ベー. 置換ヘテロ芳香族ピラゾロピリジン及びglun2b受容体調節因子としてのそれらの使用
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
KR20220020917A (ko) * 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도
MX2021015500A (es) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CN114621125B (zh) * 2020-12-14 2024-07-09 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490364B1 (en) * 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물
WO2009005821A1 (en) 2007-07-03 2009-01-08 Edward Scott Carlson Support apparatus for climbing plants
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical Substituted pyrazole derivative
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
RU2499598C2 (ru) 2008-03-27 2013-11-27 Евотек Интернациональ Гмбх Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
WO2010016490A1 (ja) 2008-08-05 2010-02-11 第一三共株式会社 イミダゾピリジン-2-オン誘導体
AU2009304293B2 (en) * 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011156245A2 (en) 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
EP2970200A1 (en) * 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
RU2680100C9 (ru) * 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途

Also Published As

Publication number Publication date
JP6964576B2 (ja) 2021-11-10
CA2991765C (en) 2023-10-03
JP2021193099A (ja) 2021-12-23
BR112018000468A2 (pt) 2018-09-18
ES2781867T3 (es) 2020-09-08
DK3319963T3 (da) 2020-02-03
MD3319963T2 (ro) 2020-05-31
SI3319963T1 (sl) 2020-02-28
SMT202000134T1 (it) 2020-05-08
PT3319963T (pt) 2020-04-09
HUE047460T2 (hu) 2020-04-28
EA201890245A1 (ru) 2018-06-29
ZA201800827B (en) 2019-09-25
MA42397B1 (fr) 2020-02-28
KR20180026760A (ko) 2018-03-13
US9963447B2 (en) 2018-05-08
CA2991765A1 (en) 2017-01-12
US20180208595A1 (en) 2018-07-26
HK1255160A1 (en) 2019-08-09
LT3319963T (lt) 2020-03-25
IL256758A (en) 2018-03-29
CN108026094B (zh) 2021-02-09
AU2016291158A1 (en) 2018-02-01
EP3319963B1 (en) 2020-01-08
CN108026094A (zh) 2018-05-11
AU2016291158B2 (en) 2020-04-30
CY1123007T1 (el) 2021-10-29
PL3319963T3 (pl) 2020-06-01
US20170008890A1 (en) 2017-01-12
US10377753B2 (en) 2019-08-13
EA033197B1 (ru) 2019-09-30
WO2017007938A1 (en) 2017-01-12
JP7369743B2 (ja) 2023-10-26
JP2018520170A (ja) 2018-07-26
MX2018000352A (es) 2018-08-15
EP3319963A1 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
HRP20200410T1 (hr) Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
JP2018520170A5 (cg-RX-API-DMAC7.html)
JP2016523911A5 (cg-RX-API-DMAC7.html)
JP6482086B2 (ja) 疾患の治療に有用な複素環化合物
RU2659070C9 (ru) ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
JP2011500806A5 (cg-RX-API-DMAC7.html)
JP2016519156A5 (cg-RX-API-DMAC7.html)
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
JP2014506877A5 (cg-RX-API-DMAC7.html)
RU2015154987A (ru) Гетероциклические производные
JP2019523233A5 (cg-RX-API-DMAC7.html)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2016523925A5 (cg-RX-API-DMAC7.html)
JP2016534023A5 (cg-RX-API-DMAC7.html)
US9809573B2 (en) Substituted pyridine derivatives useful as GSK-3 inhibitors
RU2016112952A (ru) Производные индола и индазола
RU2013125337A (ru) Производные триазола и их применение при неврологических заболеваниях
ME02856B (me) Aminopirimidinilni spojevi kao inhibitori jak
RU2018142987A (ru) Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m4
RU2021133444A (ru) Производные бензимидазола в качестве модуляторов ror-гамма
HRP20151077T1 (hr) Derivati pirazola
IL276998B1 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
JP5872069B2 (ja) 微量アミン関連受容体(taar)としての複素環誘導体
HRP20241375T1 (hr) Spojevi modulatora gpr52
RU2010119560A (ru) Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение